{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:09:57Z","timestamp":1787170197977,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Inner Mongolia Autonomous Region Health Commission, Inner Mongolia Medical Sciences Academy","award":["2023GLLH0018"],"award-info":[{"award-number":["2023GLLH0018"]}]},{"name":"Inner Mongolia Autonomous Region Health Commission, Inner Mongolia Medical Sciences Academy","award":["2023GLLH0018"],"award-info":[{"award-number":["2023GLLH0018"]}]},{"name":"Inner Mongolia Autonomous Region Health Commission, Inner Mongolia Medical Sciences Academy","award":["2023GLLH0018"],"award-info":[{"award-number":["2023GLLH0018"]}]},{"name":"Inner Mongolia Autonomous Region Health Commission, Inner Mongolia Medical Sciences Academy","award":["2023GLLH0018"],"award-info":[{"award-number":["2023GLLH0018"]}]},{"name":"Inner Mongolia Autonomous Region Health Commission, Inner Mongolia Medical Sciences Academy","award":["2023GLLH0018"],"award-info":[{"award-number":["2023GLLH0018"]}]},{"name":"Inner Mongolia Autonomous Region Health Commission, Inner Mongolia Medical Sciences Academy","award":["2023GLLH0018"],"award-info":[{"award-number":["2023GLLH0018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-15232-0","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T12:20:40Z","timestamp":1756210840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Screening of SGLT2 inhibitors based on virtual screening and cellular experiments"],"prefix":"10.1038","volume":"15","author":[{"given":"Dan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7752-5173","authenticated-orcid":false,"given":"Lei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Ling","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Rong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"issue":"3","key":"15232_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/jdi.13157","volume":"11","author":"K Sada","year":"2020","unstructured":"Sada, K. et al. Clinical and genetic analysis in a family with familial renal glucosuria: Identification of an N101K mutation in the sodium-glucose cotransporter 2 encoded by a solute carrier family 5member 2 gene. J. Diabetes Investig. 11(3), 573\u2013577 (2020).","journal-title":"J. Diabetes Investig."},{"issue":"6","key":"15232_CR2","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s00439-002-0820-5","volume":"111","author":"LP van den Heuvel","year":"2022","unstructured":"van den Heuvel, L. P. et al. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum. Genet. 111(6), 544\u2013547 (2022).","journal-title":"Hum. Genet."},{"issue":"7","key":"15232_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.arcped.2020.07.002","volume":"27","author":"D Djeddi","year":"2020","unstructured":"Djeddi, D. et al. Persistently high urine glucose levels caused by familial renal glycosuria. Arch. Pediatr. 27(7), 386\u2013387 (2020).","journal-title":"Arch. Pediatr."},{"issue":"1","key":"15232_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12882-020-01725-9","volume":"21","author":"Yu Lei","year":"2020","unstructured":"Lei, Yu. et al. SLC5A2 mutations, including two novel mutations, responsible for renal glucosuria in Chinese families. BMC Nephrol. 21(1), 69 (2020).","journal-title":"BMC Nephrol."},{"issue":"1","key":"15232_CR5","doi-asserted-by":"publisher","first-page":"e14948","DOI":"10.1111\/ped.14948","volume":"64","author":"S Dorum","year":"2022","unstructured":"Dorum, S. et al. Clinical features of pediatric renal glucosuria cases due to SLC5A2 gene variants. Pediatr. Int. 64(1), e14948 (2022).","journal-title":"Pediatr. Int."},{"issue":"1","key":"15232_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010252","volume":"6","author":"M Chen","year":"2016","unstructured":"Chen, M. et al. Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: Protocol for a systematic review and network meta-analysis. BMJ Open 6(1), e010252 (2016).","journal-title":"BMJ Open"},{"issue":"7","key":"15232_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrd3180","volume":"9","author":"EC Chao","year":"2010","unstructured":"Chao, E. C. & Henry, R. R. SGLT2 inhibition\u2014A novel strategy for diabetes treatment. Nat. Rev. Drug. Discov. 9(7), 551\u2013559 (2010).","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"11","key":"15232_CR8","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1007\/s11255-014-0755-5","volume":"46","author":"Yu Lei","year":"2014","unstructured":"Lei, Yu. et al. A novel sodium-glucose co-transporter 2 gene (SGLT2) mutation contributes to the abnormal expression of SGLT2 in renal tissues in familial renal glucosuria. Int. Urol. Nephrol. 46(11), 2237\u20132238 (2014).","journal-title":"Int. Urol. Nephrol."},{"key":"15232_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12882-016-0244-4","volume":"17","author":"L Yu","year":"2016","unstructured":"Yu, L. et al. Decreased expression and function of sodium-glucose co-transporter 2 from a novel C-terminal mutation: a case report. BMC Nephrol. 17, 31 (2016).","journal-title":"BMC Nephrol."},{"issue":"3","key":"15232_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00439-010-0927-z","volume":"129","author":"L Yu","year":"2011","unstructured":"Yu, L. et al. Abnormal expression and dysfunction of novel SGLT2 mutations identified in familial renal glucosuria patients. Hum. Genet. 129(3), 335\u2013344 (2011).","journal-title":"Hum. Genet."},{"issue":"1","key":"15232_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/humu.22714","volume":"36","author":"L Yu","year":"2015","unstructured":"Yu, L. et al. Novel SLC5A2 variants contribute to renal glucosuria in Chinese families: Abnormal expression and dysfunction of variant SLC5A2. Hum. Mutat. 36(1), 79\u201386 (2015).","journal-title":"Hum. Mutat."},{"issue":"2","key":"15232_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3892\/etm.2016.3388","volume":"12","author":"L Yu","year":"2016","unstructured":"Yu, L. et al. Novel SLC5A2 mutation contributes to familial renal glucosuria: Abnormal expression in renal tissues. Exp. Ther. Med. 12(2), 649\u2013652 (2016).","journal-title":"Exp. Ther. Med."},{"key":"15232_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","volume":"138","author":"NH Cho","year":"2018","unstructured":"Cho, N. H. et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Clin. Pract. 138, 271\u2013281 (2018).","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"1","key":"15232_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/dmrr.532","volume":"21","author":"JRL Ehrenkranz","year":"2005","unstructured":"Ehrenkranz, J. R. L. et al. Phlorizin: A review. Diabetes Metab. Res. Rev. 21(1), 31\u201338 (2005).","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"3","key":"15232_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4103\/2229-516X.165363","volume":"5","author":"A Malhotra","year":"2015","unstructured":"Malhotra, A. et al. Sodium glucose co-transporter inhibitors\u2014A new class of old drugs. Int. J. Appl. Basic Med. Res. 5(3), 161\u2013163 (2015).","journal-title":"Int. J. Appl. Basic Med. Res."},{"issue":"12","key":"15232_CR16","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","volume":"61","author":"MJ Davies","year":"2018","unstructured":"Davies, M. J. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61(12), 2461\u20132498 (2018).","journal-title":"Diabetologia"},{"key":"15232_CR17","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care, 45(Suppl 1), s144\u2013S174 (2022).","DOI":"10.2337\/dc22-S010"},{"issue":"2","key":"15232_CR18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire, D. K. et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis. JAMA Cardiol. 6(2), 148\u2013158 (2021).","journal-title":"JAMA Cardiol."},{"issue":"1","key":"15232_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1089\/pancan.2018.0016","volume":"4","author":"DJ Pace","year":"2018","unstructured":"Pace, D. J. et al. Euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter 2 inhibitor use in two patients undergoing pancreatectomy. J. Pancreat. Cancer 4(1), 95\u201399 (2018).","journal-title":"J. Pancreat. Cancer"},{"issue":"9","key":"15232_CR20","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jfma.2018.02.004","volume":"117","author":"YH Lin","year":"2018","unstructured":"Lin, Y. H. Sodium-glucose cotransporter-2 inhibitors induced EU-glycemic diabetic ketoacidosis: The first report in a type 2 diabetic (T2D) Taiwanese and literature review of possible pathophysiology and contributing factors. J. Formos. Med. Assoc. 117(9), 849\u2013854 (2018).","journal-title":"J. Formos. Med. Assoc."},{"issue":"3","key":"15232_CR21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.4067\/S0370-41062017000300015","volume":"88","author":"AM Pereyra","year":"2017","unstructured":"Pereyra, A. M., Ram\u00edrez, C. & Rom\u00e1n, R. Euglycemic ketosis in an adolescent with type 1 diabetes on insulin and dapaglifozin: Case report. Rev. Chil. Pediatr. 88(3), 404\u2013410 (2017).","journal-title":"Rev. Chil. Pediatr."},{"issue":"3","key":"15232_CR22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.13286\/j.cnki.chinhosppharmacyj.03.14","volume":"39","author":"Z Lu","year":"2019","unstructured":"Lu, Z. et al. Literature analysis of 22 cases of ketoacidosis caused by sodium-glucose co-transporter protein 2 inhibitors. Chin. J. Hosp. Pharm. 39(3), 282\u2013286. https:\/\/doi.org\/10.13286\/j.cnki.chinhosppharmacyj.03.14 (2019).","journal-title":"Chin. J. Hosp. Pharm."},{"issue":"3","key":"15232_CR23","first-page":"271","volume":"18","author":"J Cai","year":"2021","unstructured":"Cai, J., Wei, J. & Ji, L. Two cases of euglycemic diabetic ketosis induced by dapagliflozin tablets. China Pharm. 18(3), 271\u2013273 (2021).","journal-title":"China Pharm."},{"issue":"14","key":"15232_CR24","first-page":"2510","volume":"32","author":"YX Qi","year":"2023","unstructured":"Qi, Y. X. et al. Literature analysis of sodium - glucose cotransporter 2 inhibitor related ketosis\/ketoacidosis. Henan Med. Res. 32(14), 2510\u20132512 (2023).","journal-title":"Henan Med. Res."},{"issue":"2","key":"15232_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/03007995.2017.1392293","volume":"34","author":"M Goda","year":"2018","unstructured":"Goda, M. et al. Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: A 1-year post-marketing surveillance in Japan. Curr. Med. Res. Opin. 34(2), 319\u2013327 (2018).","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"15232_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.clinthera.2013.11.002","volume":"36","author":"LN Ji","year":"2014","unstructured":"Ji, L. N. et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: A randomized, blinded, prospective phase III study. Clin Ther 36(1), 84-100.e9 (2014).","journal-title":"Clin Ther"},{"key":"15232_CR27","unstructured":"Lu, J., Yu, S., Tong, F. et al. One case of severe constipation caused by dapagliflozin. China Pharmacovigilance. pp .1\u20137."},{"issue":"4","key":"15232_CR28","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"DE Kohan","year":"2014","unstructured":"Kohan, D. E. et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 85(4), 962\u2013971 (2014).","journal-title":"Kidney Int."},{"issue":"5","key":"15232_CR29","doi-asserted-by":"publisher","first-page":"147916412095362","DOI":"10.1177\/1479164120953625","volume":"17","author":"X Rong","year":"2020","unstructured":"Rong, X. et al. Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials. Diab. Vasc. Dis. Res. 17(5), 1479164120953625 (2020).","journal-title":"Diab. Vasc. Dis. Res."},{"issue":"8","key":"15232_CR30","first-page":"603","volume":"52","author":"S Zhang","year":"2023","unstructured":"Zhang, S., Zhu, D. Q. & Hou, X. Y. Progress of research on the correlation between hypoglycemic drugs and sarcopenia in patients with type 2 diabetes mellitus. Shanxi Med. Mag. 52(8), 603\u2013609 (2023).","journal-title":"Shanxi Med. Mag."},{"issue":"2","key":"15232_CR31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/1573409916666200213124929","volume":"17","author":"I Boulhissa","year":"2021","unstructured":"Boulhissa, I. et al. Investigation of new inhibitors of UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) by virtual screening with antibacterial assessment. CAD 17(2), 214\u2013224 (2021).","journal-title":"CAD"},{"issue":"4","key":"15232_CR32","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/jcc.21643","volume":"32","author":"D Plewczynski","year":"2011","unstructured":"Plewczynski, D. et al. Can we trust docking results? Evaluation of seven commonly used programs on PDBbind database. J. Comput. Chem. 32(4), 742\u2013755 (2011).","journal-title":"J. Comput. Chem."},{"issue":"12","key":"15232_CR33","first-page":"930","volume":"33","author":"J Li","year":"2023","unstructured":"Li, J. et al. Application of computer-aided drug design in antiviral drug research. Chin. J. Med. Chem. 33(12), 930\u2013947 (2023).","journal-title":"Chin. J. Med. Chem."},{"issue":"17","key":"15232_CR34","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.2174\/0115701808306787240709073814","volume":"21","author":"A Guendouze","year":"2024","unstructured":"Guendouze, A. et al. Exploring the potential of avenanthramides and their analogues as \u03b1-glucosidase inhibitors for type 2 diabetes treatment utilizing virtual screening, molecular dynamics, and drug-likeness predictions. LDDD 21(17), 3858\u20133871 (2024).","journal-title":"LDDD"},{"issue":"3","key":"15232_CR35","doi-asserted-by":"publisher","first-page":"398","DOI":"10.17776\/csj.1063966","volume":"43","author":"ME Hassen","year":"2022","unstructured":"Hassen, M. E. et al. Molecular docking and drug-likeness prediction of new potent tubulin colchicine binding site inhibitors for potential antitumor drug. Cumhuriyet Sci. J. 43(3), 398\u2013403 (2022).","journal-title":"Cumhuriyet Sci. J."},{"issue":"8","key":"15232_CR36","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1023\/A:1008158231558","volume":"14","author":"GM Verkhivker","year":"2000","unstructured":"Verkhivker, G. M. et al. Deciphering common failures in molecular docking of ligand-protein complexes. J. Comput. Aided Mol. Des. 14(8), 731\u2013751 (2000).","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"W1","key":"15232_CR37","doi-asserted-by":"publisher","first-page":"w432","DOI":"10.1093\/nar\/gkae298","volume":"52","author":"Y Gu","year":"2024","unstructured":"Gu, Y. et al. admetSAR3.0: A comprehensive platform for exploration, prediction and optimization of chemical ADMET properties. Nucl. Acids Res. 52(W1), w432-W438 (2024).","journal-title":"Nucl. Acids Res."},{"key":"15232_CR38","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 42717 (2017).","journal-title":"Sci. Rep."},{"issue":"2","key":"15232_CR39","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3390\/molecules28020776","volume":"28","author":"J Dulsat","year":"2023","unstructured":"Dulsat, J. et al. Evaluation of free online ADMET tools for academic or small biotech environments. Molecules 28(2), 776 (2023).","journal-title":"Molecules"},{"issue":"7","key":"15232_CR40","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00467-012-2109-9","volume":"27","author":"HK Lee","year":"2012","unstructured":"Lee, H. K. et al. Familial renal glucosuria: A clinicogenetic study of 23 additional cases. Pediatr. Nephrol. 27(7), 1091\u20131095 (2012).","journal-title":"Pediatr. Nephrol."},{"issue":"9","key":"15232_CR41","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMc1602469","volume":"5","author":"LX Zhang","year":"2016","unstructured":"Zhang, L. X. et al. Trends in chronic kidney disease in China. N Engl J Med 5(9), 905\u2013906 (2016).","journal-title":"N Engl J Med"},{"key":"15232_CR42","doi-asserted-by":"publisher","first-page":"1497449","DOI":"10.1155\/2021\/1497449","volume":"2021","author":"N Samsu","year":"2021","unstructured":"Samsu, N. Diabetic nephropathy: Challenges in pathogenesis, diagnosis, and treatment. Biomed. Res. Int. 2021, 1497449 (2021).","journal-title":"Biomed. Res. Int."},{"key":"15232_CR43","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.phrs.2016.07.001","volume":"118","author":"J-L Faillie","year":"2017","unstructured":"Faillie, J.-L. Pharmacological aspects of the safety of gliflozins. Pharmacol. Res. 118, 71\u201381 (2017).","journal-title":"Pharmacol. Res."},{"issue":"5","key":"15232_CR44","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1172\/JCI112981","volume":"79","author":"L Rossetti","year":"1987","unstructured":"Rossetti, L. et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J. Clin. Invest. 79(5), 1510\u20131515 (1987).","journal-title":"J. Clin. Invest."},{"issue":"Suppl 2","key":"15232_CR45","doi-asserted-by":"publisher","first-page":"105","DOI":"10.6002\/ect.IAHNCongress.25","volume":"21","author":"\u00d6 Helvac\u0131","year":"2023","unstructured":"Helvac\u0131, \u00d6. & Helvac\u0131, B. A story of serendipities: From phlorizin to gliflozins. Exp. Clin. Transplant. 21(Suppl 2), 105\u2013108 (2023).","journal-title":"Exp. Clin. Transplant."},{"key":"15232_CR46","doi-asserted-by":"publisher","first-page":"12.14.1","DOI":"10.1002\/0471141755.ph1214s71","volume":"71","author":"YN Yamamoto","year":"2015","unstructured":"Yamamoto, Y. N. et al. Measurement of Glucose Uptake in Cultured Cells. Curr. Protoc. Pharmacol. 71, 12.14.1-12.14.26 (2015).","journal-title":"Curr. Protoc. Pharmacol."},{"issue":"1","key":"15232_CR47","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/0003-2697(90)90265-B","volume":"185","author":"JK Manchester","year":"1990","unstructured":"Manchester, J. K. et al. Measurement of 2-deoxyglucose and 2-deoxyglucose 6-phosphate in tissues. Anal. Biochem. 185(1), 118\u2013124 (1990).","journal-title":"Anal. Biochem."},{"issue":"2","key":"15232_CR48","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1006\/abio.1993.1594","volume":"215","author":"S Sasson","year":"1993","unstructured":"Sasson, S., Oron, R. & Cerasi, E. Enzymatic assay of 2-deoxyglucose 6-phosphate for assessing hexose uptake rates in cultured cells. Anal. Biochem. 215(2), 309\u2013311 (1993).","journal-title":"Anal. Biochem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15232-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15232-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15232-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T18:43:38Z","timestamp":1757443418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15232-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15232"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-15232-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31411"}}